Company Directory - H. Lundbeck A/S
Company Details - H. Lundbeck A/S
H. Lundbeck A/S
WebsiteBagsværd, Denmark
ISIN: DK0060030975
H. Lundbeck A/S is a global pharmaceutical company specializing in the discovery, development, manufacturing, and marketing of medications for brain diseases.
CCI Score
CCI Score: H. Lundbeck A/S
16.06
-0.01%
Latest Event
H Lundbeck A/S Lobbying Spending in 2024
H Lundbeck A/S spent $550,000 on lobbying activities in 2024, as reported by OpenSecrets. This expenditure highlights the company’s active political engagement through lobbying, which can contribute to regulatory capture and undemocratic influence.
Take Action
So what can you do? Support Lundbeck by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
H. Lundbeck A/S is currently rated as a Saboteur.
Latest Events
- JAN012024
H Lundbeck A/S spent $550,000 on lobbying activities in 2024, as reported by OpenSecrets. This expenditure highlights the company’s active political engagement through lobbying, which can contribute to regulatory capture and undemocratic influence.
-60
Political Contributions and Lobbying Efforts
March 28
The company's expenditure of $550,000 on lobbying in 2024 indicates a significant investment in influencing political processes. From an anti-fascist perspective, such political lobbying by large corporations can undermine democratic accountability and facilitate regulatory capture, thus earning a negative score.
- DEC312023
According to OpenSecrets, H Lundbeck A/S spent $450,000 on lobbying activities in 2023, an effort that may be aimed at influencing policy decisions in favor of the company’s interests.
-40
Political Contributions and Lobbying Efforts
March 28
The reported $450,000 lobbying expenditure indicates a significant engagement in political lobbying, a practice that can contribute to undue corporate influence on public policy. From an anti-fascist perspective, such lobbying efforts risk prioritizing corporate interests over democratic accountability and the rights of marginalized groups.
- DEC312023
H. Lundbeck A/S published a detailed report outlining its due diligence processes, supplier audits, and corrective measures to prevent forced labour and child labour in its supply chain during the reporting period ending December 31, 2023.
+80
Labor Relations and Human Rights Practices
March 28
The report demonstrates a strong commitment to labor rights and human rights practices through rigorous due diligence processes, comprehensive audits, and mandatory training for employees, ensuring that forced labour and child labour are aggressively mitigated. This proactive measure helps protect vulnerable workers and aligns with anti-authoritarian, ethical labor standards.
PDF Report Pursuant to the Fighting Against Forced Labour and Child Labour ...
+70
Supply Chain Ethics
March 28
The report outlines stringent supply chain transparency measures including detailed supplier evaluations, on-site audits, and corrective action plans tailored to mitigate risks associated with forced and child labour. Such rigorous monitoring enhances accountability and ethical sourcing practices.
PDF Report Pursuant to the Fighting Against Forced Labour and Child Labour ...
- OCT012023
H. Lundbeck A/S published its Code of Conduct detailing a commitment to ethical compliance, adherence to legal and regulatory standards, and alignment with international practices such as the IFPMA Code of Practice. The statement emphasizes internal accountability and sets out expectations for all employees and third-party collaborators.
+60
Business Practices and Ethical Responsibility
March 28
The company's publication of a comprehensive Code of Conduct demonstrates a proactive commitment to ethical business practices and responsible corporate behavior, which can help mitigate risks associated with authoritarian influences. This clear adherence to sustainability and compliance standards reinforces progressive values in business practices.
- JAN012023
H. Lundbeck A/S spent $450,000 on lobbying efforts in 2023, as detailed in lobbying reports from OpenSecrets. This expenditure highlights the company's engagement in influencing public policy through financial contributions to lobbying activities.
-40
Political Contributions and Lobbying Efforts
March 28
The reported $450,000 spent on lobbying in 2023 raises concerns about corporate influence over public policy. From an anti-fascist perspective, such significant political spending can erode democratic accountability and empower authoritarian interests by prioritizing corporate objectives over public welfare.
- JAN012023
Lundbeck has introduced comprehensive due diligence and monitoring procedures for its suppliers and third-party collaborators. The measures are designed to address conflicts of interest, financial crime, promotional misconduct, human and labour rights violations, and significant environmental impact, aligning with UN Global Compact Principles and OECD Guidelines.
+80
Labor Relations and Human Rights Practices
March 28
Lundbeck’s due diligence procedures explicitly include monitoring for human and labour rights violations, underscoring its commitment to ethical labor practices. Such measures help protect vulnerable workers and promote fair labor standards.
+80
Supply Chain Ethics
March 28
The company’s structured approach to screening and monitoring suppliers addresses conflicts of interest, corruption risks, and environmental impacts. This proactive supply chain ethics policy reinforces Lundbeck’s commitment to ethical business practices.
- JAN012020
H. Lundbeck A/S has outlined its 2020 sustainability strategy aligning with the UN Sustainable Development Goals, emphasizing commitments to human and labour rights, environmental protection, and anti-corruption measures.
+80
Labor Relations and Human Rights Practices
March 28
The sustainability strategy demonstrates a proactive commitment to upholding human and labour rights and ethical business practices by aligning with the UN Sustainable Development Goals. This initiative supports progressive values, emphasizing fair labor practices and corporate responsibility.
- MAR292012
In response to the discovery that its pentobarbital was being used by certain US prisons for capital punishment, Lundbeck took swift action by alerting prison and public authorities and consulting with NGOs. The company then established a revised distribution program to ensure its product remained available for legitimate medical purposes while restricting access that could facilitate executions. This initiative earned Lundbeck an award from legal action charity Reprieve for its ethical leadership in the pharmaceutical industry.
+70
Public and Political Behavior
March 28
Lundbeck demonstrated proactive public and political behavior by alerting prison authorities and public officials about the misuse of its medication, engaging with NGOs and experts to address an ethical crisis linked to capital punishment. This outreach represents a commendable effort to uphold transparency and ethical responsibility in the face of potential misuse of their products.
Lundbeck awarded for ethical leadership in the pharmaceutical industry
+80
Supply Chain Ethics
March 28
By swiftly instituting a new distribution program that ensured its medication would not be available to prisons in death penalty states, Lundbeck exemplified robust ethical business practices. This decisive supply chain management mitigated the risk of misuse and underscored the company's commitment to responsible corporate conduct.
Lundbeck awarded for ethical leadership in the pharmaceutical industry
Alternatives
Copenhagen, Denmark
2.36
Belgium (Ghent), Belgium
79.03
Raleigh, USA
56.52
New York, United States
30.41
Kenilworth, United States
12.75
Darmstadt, Germany
12.29
Kenilworth, United States
2.89
Pasadena, United States
0.00
Cranbury, United States
-15.14
Basel, Switzerland
-19.75
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 423450
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 541711
- Research and Development in Biotechnology